|
1. Biologie
|
|
|
|
2.5 Etiologie - Gènes
|
|
|
The (bad) luck of the draw; more evidence [The Mermaid's Tale]
|
|
|
|
|
|
The
silly extremism to which the objectors to V-T would take us would be to
say that, obviously, if we avoided any interaction whatsoever with our
environment, we'd never get cancer. Of course, we'd all be so demented
and immobilized with diverse organ-system failures that we wouldn't
realize our good fortune in not getting cancer.
|
|
|
|
|
|
|
3.3 Prévention - Vaccins
|
|
|
|
4.12 Biopsies liquides
|
|
|
Penn Studies Find Promise for Innovations in Liquid Biopsies [Penn Medicine]
|
|
|
|
|
|
From
using fluid in the lungs to better understand the potential of
immunotherapy treatments in lung cancer, to tracking circulating tumor
cells in prostate cancer, to conducting RNA sequencing of cancer cell
clusters from the blood of pancreatic cancer patients, to finding new
ways to biopsy tissue from patients who may have esophageal cancer, a
series of studies from the Perelman School of Medicine at the University
of Pennsylvania demonstrate the promise of new diagnostic methods.
|
|
|
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
Detecting, diagnosing women’s cancers in new ways [WUSTL]
|
|
|
|
|
|
Quing
Zhu, professor of biomedical engineering with a secondary appointment
as a professor of radiology at the School of Medicine, combines
ultrasound with two additional optical imaging components — diffused
near infrared light and photoacoustic waves — to give doctors a more
accurate understanding of a patient’s tumor and how to best treat it.
|
|
|
|
|
|
|
|
|
5. Traitements
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
|
|
|
5.12.3 Immunothérapies-combinaisons
|
|
|
|
5.2 Pharma
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
|
F.D.A. Nominee Details Millions in Payments From Drug Firms [NY Times]
|
|
|
|
|
|
Dr.
Gottlieb is the acting chief executive of Cell Biotherapy, an
early-stage cancer biotech firm that he helped found. He has served for
years as a consultant to pharmaceutical giants like GlaxoSmithKline and
Bristol-Myers Squibb and is paid by other companies for his expertise.
|
|
|
|
|
|
|
EU rapid drug approval plan worries some national agencies [Reuters]
|
|
|
|
|
|
France
is another country to voice scepticism about the EMA's new approach and
some smaller countries have expressed misgivings privately. France's
Haute Autorite de Sante, for example, says it has "mixed feelings" about
expanding existing conditional marketing approval rules, according to
Chantal Belorgey, its director in charge of medical assessment.
|
|
|
|
|
|
|
6.1 Observation
|
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
Trump wants 2018 NIH cut to come from overhead payments [Science]
|
|
|
|
|
|
University
and research institutions, which negotiate their indirect cost recovery
rates with the federal government, say the amount they receive doesn’t
come close to covering the cost of the facilities needed to conduct
federally funded research and the people needed to manage those grants.
|
|
|
|
|
|
|
6.6 Publications
|
|
|
European Commission considering leap into open-access publishing [Science]
|
|
|
|
|
|
The
European Commission, which spends more than €10 billion annually on
research, may follow two other big league funders, the Wellcome Trust
and the Bill & Melinda Gates Foundation, and set up a “publishing
platform” for the scientists it funds, in an attempt to accelerate the
transition to open-access publishing in Europe.
|
|
|
|
|
|
|